Radretumab is an antineoplastic. Philogen, a pharmaceutical company specializing in antibody-drug conjugates, is developing it as a conjugate of Iodine-131 to an antibody which binds to fibronectin extra domain-B for treatment of Hodgkin lymphoma.[1][2][3]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | fibronectin |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
  (what is this?) (verify) | |
References
edit- ^ "Radretumab (L19-131I)". Philogen. Archived from the original on 6 November 2017.
- ^ World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104" (PDF). WHO Drug Information. 24 (4).
- ^ Erba PA, Sollini M, Orciuolo E, Traino C, Petrini M, Paganelli G, Bombardieri E, Grana C, Giovannoni L, Neri D, Menssen HD, Mariani G (June 2012). "Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies". Journal of Nuclear Medicine. 53 (6): 922–7. doi:10.2967/jnumed.111.101006. PMID 22577235. S2CID 26518175.922-7&rft.date=2012-06&rft_id=https://api.semanticscholar.org/CorpusID:26518175#id-name=S2CID&rft_id=info:pmid/22577235&rft_id=info:doi/10.2967/jnumed.111.101006&rft.aulast=Erba&rft.aufirst=PA&rft.au=Sollini, M&rft.au=Orciuolo, E&rft.au=Traino, C&rft.au=Petrini, M&rft.au=Paganelli, G&rft.au=Bombardieri, E&rft.au=Grana, C&rft.au=Giovannoni, L&rft.au=Neri, D&rft.au=Menssen, HD&rft.au=Mariani, G&rft_id=https://doi.org/10.2967%2Fjnumed.111.101006&rfr_id=info:sid/en.wikipedia.org:Radretumab" class="Z3988">
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |